Pioneering Pharmaceuticals is listed on the Hong Kong Stock Exchange today! Prostate cancer new drug procromine commercialised

On May 22nd, Innovative PharmaceuticalS Enterprise Pioneer Pharmaceuticals was officially listed on the Hong Kong Stock ExchangeThe IPO, which will be the sole sponsor of Huatai International, will issue 92.3475 million shares, with a single share priced at HK$20.15 and raising HK$1,854 millionAccording to the pharmaceutical rubu investeGo search found that the pioneering pharmaceutical industry before the IPO completed a total of 5 rounds of financing, access to Lenovo Star, Hongyu Capital, Yuansheng Ventures, Matsuo Capital and Shanghai Free Trade Zone Fund and other well-known institutionsOn the eve of the listing, Venture Pharmaceuticals received $115 million in cornerstone investment from three cornerstone investorsOf these, Greegold charged $98 million, or about 42.7 percent of the fundraisingIt is worth mentioning that this is the first time that Greegold has participated in the IPO of Hong Kong stocks as a cornerstone investorcore products: Prostate cancer new drug pukruamine commercialization in thepioneer pharmaceutical industry was established in March 2009, is committed to small molecules of anti-cancer drugs research and developmentFounded 11 years ago, the current pipeline of the pharmaceutical industry has 5 in China or the United States in the clinical trial stage of the drug research, covering prostate cancer, hair loss, breast cancer, liver cancer and other diseases treatment areasAmong them, Pukruamine is the fastest-growing clinical project in the pioneering pharmaceutical industryPukruamine, a second-generation AR antagonist used to treat metastatic resistance to prostate cancer (mCRPC), is currently in Phase III clinical trials in China, in the U.SPhase II clinical trials, and is expected to be submitted in China in 2020 for new drug marketing applications (NDA)Prostate cancer is one of the top 10 most common cancers in the United States and the world, and one of the fastest growing in China, according to Frost SullivanAmong them, Nzalamine, acetate abitron and erythlin are the top three drugs in the global prostate cancer drug market in 2018, with sales of $3,657 million, $3.498 billion and $1,049 million, respectivelyTotal sales of the three drugs accounted for 69.8% of the global prostate cancer marketAmong them, Nzalaluma, a second-generation AR antagonist developed by Astellas, was first approved in the U.Sin August 2012 and approved in China in November 2019 As of May 20, 2020, there are 7 enterprises in China layout Nzalamine generic drugs, including Colum Pharmaceuticals, Zhengda Tianqing and other 6 enterprises have been clinically approved Abitron, an androgen biosynthetic inhibitor developed by Johnson and Johnson, was first approved in the U.S on April 28, 2011, was approved in China on May 6, 2015, and included in China's National Health Insurance Drug Catalog in 2017 According to public information, Abitron achieved sales of 837 million yuan in China in 2018, making it the largest prostate cancer drug in China (20.9%) in the market as of May 20, 2020, the domestic has Hengrui Pharmaceuticals, Zhengda Tianqing, Jiangxi Shanxiang Pharmaceuticals and Qilu Pharmaceuticals 4 enterprises to complete abitron's generic drug consistency evaluation In December 2019, the second batch of national band procurement, Hengrui Pharmaceuticals, Zhengdaya Tianqing and Jiangxi Shanxiang Pharmaceuticals successfully won the bid price of 3828 yuan / box, 2800 yuan / box, 4296 yuan / box, the original Research Johnson regret out pukrumine will face competition from Nzalamine, Abitron and generics when it is approved How to maximize the commercial value of Pukruamine will be the key to the initial profit ability of the pioneering pharmaceutical industry other products under research: multi-level layout potential hot target
in addition to pukrumine, the pioneering pharmaceutical industry also has a number of drugs in research The following are of particular concern: Foraya (KX-826) acquired Suzhou Kaiju In 2018, is a targeted drug designed to treat androgen hair loss local applications, directly on the scalp's targeted treatment site, to locally block androgen-mediated signal transmission Pioneering Pharmaceuticals expects to start patient recruitment in Phase II clinical trials of Ferritan for androgen hair loss in China in 2020 Q3, and complete the trial by the end of 2020 On April 17, 2020, The Pioneering Pharmaceuticals and Guomedicine Holdings signed a Strategic Cooperation Agreement on Forrestan The two sides on patient-centered product design, future commercial channel development and terminal services and other aspects of a full range of cooperation ALK-1 (GT90001) is a potential first-in-class angiogenesis inhibitor that is expected to become the world's first all-human-derived monoclonal antibody therapeutic drug for ALK-1 targets ALK-1 was developed by Pfizer, and Pioneer Pharmaceuticals reached an agreement with Pfizer in February 2018 to acquire its exclusive global development, production and sales rights Currently, Phase II clinical trials of ALK-1 and Navuriu monoantigen treatment for patients with metastatic hepatocellular carcinoma (HCC) are under way in Taiwan, China, and are expected to be completed in 2020 In addition, the MRCT acceptance notice for ALK-1 single-drug and combination therapy has been approved by The CDE in China Dittosati (GT0486) is a new mTORC1/mTORC2 inhibitor (2nd generation mTOR inhibitor) for the treatment of patients with advanced solid tumors and is currently being treated in Phase I clinical trials for metastatic solid tumors in China To date, there is no second-generation mTOR inhibitor available worldwide However, the new generation of mTORC1/mTORC2 bi-kinase inhibitors from Takeda, AstraZeneca, Xinke, Roxin Pharmaceuticals and Xuno Pharmaceuticals have all entered the clinical trial stage The GT1708F is a Hedgehog (Hh) signaling pathway SMO inhibitor intended for the treatment of solid and blood tumors, acquired in June 2019 from Suzhou Yunxuan Pharmaceutical Technology Co., Ltd so far, three SMO antagonists have been approved for the market worldwide, including Glasdegib, developed by Roche's Vismodegib, Novartis' Sonidegib and Pfizer At present, China has not yet approved similar products On February 17, 2020, GT1708F was approved by the InD Of the National Drug Administration and is expected to begin recruiting patients in 2020Q3 in addition to the five products in clinical trials, The pioneering pharmaceutical industry currently has three products in the preclinical research phase, including AR degradation drugs intended for prostate cancer and AR-related diseases, c-Myc inhibitors intended for blood cancer treatment, and IDO inhibitors intended for a variety of cancer treatments the future profitability of the concern
According to the prospectus disclosed that so far, the pioneering pharmaceutical industry has not yet made a profit and is in a state of sustained losses, operating losses in 2018 and 2019 reached 105 million yuan, 229 million yuan, respectively, the main reason for the loss is that there is no product sales revenue and research and development investment increased year by year In 2018 and 2019, its research and development investment amounted to RMB 93 million and RMB 214 million, respectively Whether or not profitability is going to be the biggest concern for investors after the IPO of The Pioneering Pharmaceuticals According to the prospectus, The Pioneering Pharmaceuticals has now developed a comprehensive commercialization plan for Pukruamine, reducing the time to make a profit through the early distribution of sales and production production, The pioneering pharmaceutical industry has built its own manufacturing facility, currently consisting of a pukrumine tablet production line, and is expected to be ready for GMP production by Q3 in 2020, with an expected annual production capacity of 4 million tablets, and will gradually shift the production of Pukruamine from CMO to its own production facility sales, In June 2019, Pioneer Pharmaceuticals appointed Mr Yan Mingming, who led the China listing of products such as Zei," Trollakai and Baidayan, as vice president of sales and plans to form a sales team of more than 100 people to accelerate Pulcrua's market penetration and product marketing